{
    "id": 27596,
    "fullName": "ABL1 F317V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 F317V lies within the protein kinase domain of the Abl1 protein (UniProt.org). F317V has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL1 (PMID: 23044928, PMID: 15705718), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 11533,
                    "pubMedId": 15705718,
                    "title": "Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15705718"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11093,
                    "pubMedId": 23044928,
                    "title": "Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23044928"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "F317V",
    "createDate": "03/23/2018",
    "updateDate": "09/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 119169,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130872901T>G",
        "cDna": "c.949T>G",
        "protein": "p.F317V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18898,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F317V (NCCN.org).",
            "molecularProfile": {
                "id": 29107,
                "profileName": "BCR - ABL1 ABL1 F317V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20127,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 F317V (NCCN.org).",
            "molecularProfile": {
                "id": 29107,
                "profileName": "BCR - ABL1 ABL1 F317V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20992,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 F317V in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 29107,
                "profileName": "BCR - ABL1 ABL1 F317V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29106,
            "profileName": "ABL1 F317V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29107,
            "profileName": "BCR - ABL1 ABL1 F317V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119169,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130872901T>G",
            "cDna": "c.949T>G",
            "protein": "p.F317V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}